Stock Events

Stock Events

TransCode Therapeutics 

$8.83
93
-$0.77-7.97% Friday 20:00
+$0.17+1.93%Friday 22:25After hours

Statistics

Day High
8.71
Day Low
8.71
52W High
20.99
52W Low
3.82
Volume
176
Avg. Volume
-
Mkt Cap
8.1M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18AugExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-56
-37.53
-19.05
-0.58
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-33.57MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RNAZ. It's not an investment recommendation.
NVIDIA
11
NVDA
Apple
10
AAPL
Tesla
10
TSLA
Microsoft
8
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap27.09B
Moderna, Inc. focuses on mRNA-based therapies, directly competing in the genetic medicines space similar to TransCode's RNA-based treatments.
Alnylam Pharmaceuticals
ALNY
Mkt Cap41.76B
Alnylam Pharmaceuticals, Inc. specializes in RNA interference (RNAi) therapies, targeting the same RNA-based technology approach as TransCode.
Ionis Pharmaceuticals
IONS
Mkt Cap13.52B
Ionis Pharmaceuticals, Inc. develops RNA-targeted therapeutics, making it a direct competitor in the RNA-based drug development field.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap11.83B
Arrowhead Pharmaceuticals, Inc. works on medicines that silence gene expression via RNA interference, competing in the RNA therapy space.
Sarepta Therapeutics
SRPT
Mkt Cap2B
Sarepta Therapeutics, Inc. focuses on RNA-targeted drug discovery and development, particularly for rare diseases, similar to TransCode's focus on RNA.
BioNTech
BNTX
Mkt Cap23.14B
BioNTech SE partners with companies to develop mRNA-based drugs for various diseases, competing in the mRNA therapy market.
CRISPR Therapeutics
CRSP
Mkt Cap5.25B
CRISPR Therapeutics AG specializes in gene editing, a different but related field to RNA-based therapies, targeting genetic diseases at the DNA level.
Intellia Therapeutics
NTLA
Mkt Cap1.99B
Intellia Therapeutics, Inc. is involved in CRISPR/Cas9 gene editing, competing in the broader genetic medicine space that includes RNA-based therapies.
Editas Medicine
EDIT
Mkt Cap500.29M
Editas Medicine, Inc. focuses on gene editing using CRISPR technology, representing competition in the genetic medicine arena, including RNA-based approaches.

About

TransCode Therapeutics, Inc. is a biopharmaceutical firm dedicated to pioneering and marketing therapeutic agents and diagnostic tools specifically aimed at combating and detecting metastatic disease. Central to its pipeline is TTX-MC138, a lead therapeutic compound currently undergoing preclinical evaluation for its potential in treating advanced, spreading cancers. Beyond its primary candidate, the company's preclinical portfolio also features TTX-siPDL1, an siRNA designed to modulate programmed death-ligand 1, and TTX-siLIN28B, another siRNA that inhibits the RNA-binding protein LIN28B. TransCode also pursues several cancer-agnostic initiatives. These encompass TTX-RIGA, an RNA-based agent engineered to stimulate the RIG-I immune pathway within the tumor's immediate surroundings; TTX-CRISPR, a gene-editing platform utilizing CRISPR/Cas9 technology to correct or eradicate oncogenic genes within cancer cells; and TTX-mRNA, an innovative mRNA platform dedicated to creating cancer vaccines that incite powerful cytotoxic immune reactions against malignant cells. Established in 2016, TransCode Therapeutics is headquartered in Boston, Massachusetts.
Show more...
CEO
Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D.
Employees
7
Country
United States
ISIN
US89357L5012

Listings

XNAS
US
RNAZ
BOATS
BOATS
RNAZ.BOATS

0 Comments

Share your thoughts

FAQ

What is TransCode Therapeutics stock price today?▼
The current price of RNAZ is $8.83 USD — it has decreased by -7.97% in the past 24 hours. Watch TransCode Therapeutics stock price performance more closely on the chart.
What is TransCode Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange TransCode Therapeutics stocks are traded under the ticker RNAZ.
Is TransCode Therapeutics stock price growing?▼
RNAZ stock has risen by +13.64% compared to the previous week, the month change is a +65.67% rise, over the last year TransCode Therapeutics has showed a +1.67% increase.
What is TransCode Therapeutics market cap?▼
Today TransCode Therapeutics has the market capitalization of 8.1M
When is the next TransCode Therapeutics earnings date?▼
TransCode Therapeutics is going to release the next earnings report on August 18, 2026.
What is TransCode Therapeutics revenue for the last year?▼
TransCode Therapeutics revenue for the last year amounts to 0 USD.
What is TransCode Therapeutics net income for the last year?▼
RNAZ net income for the last year is -33.57M USD.
How many employees does TransCode Therapeutics have?▼
As of July 13, 2026, the company has 7 employees.
In which sector is TransCode Therapeutics located?▼
TransCode Therapeutics operates in the Health & Wellness sector.
When did TransCode Therapeutics complete a stock split?▼
The last stock split for TransCode Therapeutics was on May 15, 2025 with a ratio of 1:28.
Where is TransCode Therapeutics headquartered?▼
TransCode Therapeutics is headquartered in Boston, United States.